Doravirine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Conditions
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Trial Timeline
Mar 20, 2021 → Jun 14, 2021
NCT ID
NCT04689737About Doravirine
Doravirine is a approved stage product being developed by Merck for HIV-infected Participants With ESRD Undergoing Routine Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT04689737. Target conditions include HIV-infected Participants With ESRD Undergoing Routine Hemodialysis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05761509 | Pre-clinical | Completed |
| NCT04900974 | Phase 1 | Completed |
| NCT04689737 | Approved | Completed |
| NCT04334551 | Approved | UNKNOWN |
| NCT03894124 | Phase 1 | Completed |
| NCT02641067 | Phase 1 | Completed |
| NCT02089659 | Phase 1 | Completed |